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Abstract  
 Hypertrophic cardiomyopathy (HCM) is one of the most common 
causes of sudden cardiac death (SCD) in athletes. Knowledge of the problem 
is essential for detection of the disease. According to the current 
recommendations of the European Society of Cardiology (ESC), in individuals 
with established HCM disease, including those without phenotypic 
expression, participation in competitive sports is forbidden. The 
recommendations of the American College of Cardiology/American Heart 
Association (ACC/AHA) are more liberal, allowing participation in 
competitive sports in people with non-phenotypic manifestations of the 
disease and participation in low-intensity sports for patients with phenotypic 
manifestation. An individual approach will most likely be adopted in the 
future, mainly on the basis of precise risk stratification.  
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Introduction 
 For the first time in 1958 the English pathologist Donald Teare 
described the disease as asymmetric left ventricular hypertrophy (LVH) in 
eight adolescents (Teare, 1958). Later, the disease was called hypertrophic 
cardiomyopathy. According to the ESC, HCM is defined by the presence of 
increased left ventricular wall thickness that is not solely explained by 
increased ventricular wall tension (Elliott et al., 2014). According to the 
ACA/AHA definition, this is a disease characterized by an unexplained LVH, 
without the presence of dilation, in the absence of any other cardiac or 
systemic disease, which in itself could lead to hypertrophy (Gersh et al., 2011). 
According to the second definition, only genetically determined forms of the 
disease are taken into account.  
 A number of studies conducted in different regions of the world show 
the frequency of HCM as around 0.2% of the total population, with no 
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significant differences between the different ethnic groups and gender 
dependence (Maron, 2004). This percentage does not take into account the 
cases of death at early age, genotype-positive cases without phenotypic 
expression, and the cases with limited values of the LVH, where the diagnosis 
is controversial. Considering that information, the HCM frequency among the 
total population is probably about 0.5% (Semsarian et al., 2015).  
 It can be assumed that the frequent of HCM among the athletes is lower 
than that in the general population. This hypothesis is logical for several 
reasons: usually athletes are in childhood and young age, in which the 
incidence of the disease is lower; the early phenotypic evidence of the disease 
leads to cessation of active sporting activity; the existence of significant 
complaints in patients with HCM is incompatible with practicing of 
competitive sports, especially some of the sport disciplines, where very high 
aerobic performance is necessary.  
 
Etiology of hypertrophic cardiomyopathy  
 The most common cause of HCM’s development are gene mutations, 
which are transmitted as an autosomal dominantly trait. They affect the genes 
encoding sarcomere proteins and are responsible for 40-60% of all cases (Van 
Driest et al., 2005; Morita et al., 2008; Lopes et al., 2013). In the majority of 
cases, in genetically determined HCM, mutations of the genes encoding the 
beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) 
(70-80%) are involved. The gene mutations rarely affect troponin I and T, 
tropomyosin alpha-1 chain and myosin light chain 3. These gene mutations 
are responsible for 50-70% of all manifested HCM clinical cases (Geisterfer-
Lowrance et al., 1990; Watkins et al., 1993). Patients with proven gene 
mutations are more likely to have a positive family history and a higher risk 
of SCD (Coats et al., 2013; Olivotto et al., 2008). On the other hand, not all 
cases of gene mutations are phenotypically presented. There is still no clarity 
about the SCD risk in these individuals. Other causes of HCM development 
(according to the ESC expert group) include metabolic disorders (Anderson-
Fabry disease, Danon disease), mitochondrial cardiomyopathies, 
neuromuscular diseases, infiltrative diseases, endocrine diseases, etc. (Elliott 
et al., 2014). It should not be forgotten that in about 25-30% of cases, the cause 
of HCM development is not identified. Probably, the determining role in HCM 
genesis in athletes has the genetic mutations. There are two main reasons that 
justify this assumption: their leading role in the general population, and 
incompatibility with elite sport in some of the other mentioned above diseases 
leading to hypertrophy. 
 
 
 
European Scientific Journal March 2018 edition Vol.14, No.9 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
3 
Pathophysiology of hypertrophic cardiomyopathy 
 The hypertrophic cardiomyopathy causes a number of 
pathophysiological changes that determined most of the symptoms and 
prognosis of patients. One of the leading hemodynamic disorders is the 
presence of gradient in the left ventricular outflow tract (LVOT). This is a 
peak gradient that occurs due to obstruction, caused by a septum hypertrophy, 
papillary muscle hypertrophy, mitral valve displacement, etc. Moreover, the 
obstruction is dynamic and depends on the preload and afterload of the 
ventricle, heart rate, contractility, and other factors. About 1/3 of the patients 
have gradient above 30 mmHg at rest, another 1/3 have a gradient below 30 
mmHg at rest and above 30 mmHg after provocation, and the remaining 1/3 
have a gradient below 30 mmHg at rest as well as after provocation 
(nonobstructive form of HCM) (Maron et al., 2006). Patients with gradient 
above 50 mmHg at rest or after provocation are usually symptomatic and are 
indicated for surgical or interventional treatment. 
 Diastolic dysfunction is another significant pathophysiological 
disorder. It is due to compromised ventricular relaxation and increased 
myocardial rigidity due to intracellular calcium retention, myocardial 
hypertrophy and probable ischemia (Wigle et al., 1995). 
 The emergence of myocardial ischemia is not related to morphological 
changes in subepicardial coronary arteries. The leading cause is the imbalance 
between oxygen supply to myocardium and disproportionately increased 
oxygen demand (Maron et al., 2009). Compression of the intramural coronary 
arteries of the hypertrophied myocardium is also affected (Maron et al., 1986). 
These pathophysiological changes can lead to severe ischemia, including a 
myocardial infarction. Approximately 25% of the patients experience 
abnormal blood pressure response at exercise, and systolic levels may not rise 
by more than 20 mmHg or decrease in some cases ( Frenneaux et al., 1990; 
Sadoul et al., 1997). This reaction is probably due to a suboptimal increase in 
cardiac output caused by an obstruction and systemic vasodilatation, which 
are induced by physical loading.  
 The mitral regurgitation is a common disorder in patients with 
obstructive HCM. It is a secondary occurrence because of the valve apparatus 
deformation, and is often dynamic (Wigle et al., 1995).  In some cases, mitral 
regurgitation is hemodynamically significant.  
 It can be assumed that systemic physical workloads in athletes have 
radically opposite effects on the major pathophysiological disorders. On one 
hand, the intense physical loads can provoke increased left ventricular outflow 
gradient or myocardial ischemia. On the other hand, regular volume loading 
of the left ventricle during physical exercise may contribute to increasing its 
volume and improving the ventricular relaxation.   
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Symptoms in patients with hypertrophic cardiomyopathy 
 The disease is asymptomatic in most patients, and in the most cases 
they have a normal life expectancy. It does not limit their physical working 
capacity, and it is possible for these individuals to practice competitive sports. 
Top sporting achievements are also possible.  In some patients, the 
symptoms appear later in the evolution of the disease, years after its diagnosis. 
In other patients, symptom occurrence is the cause of HCM detection. The 
most common manifestations of HCM are fatigue and dyspnoea, chest pain, 
palpitations, presyncope and syncope, and SCD. 
 The fatigue and shortness of breath are relatively common symptoms 
and they are a manifestation of left-sided heart failure. In most cases, they are 
associated with diastolic dysfunction in the presence of a normal or a reduced 
left ventricular size and preserved systolic function. Rarely, in advanced cases 
of the disease, the left ventricle systolic function can be impaired. The 
presence of a hemodynamically significant gradient in the left ventricular 
outflow tract, and mitral insufficiency and rhythm disturbances, especially 
atrial fibrillation, may affect the appearance and severity of the symptoms. In 
athletes, the manifestations of heart failure are incompatible with competitive 
sports, especially in heavier sports disciplines.  
 Chest pain is another common symptom in HCM patients. It can occur 
at rest or during physical effort, and may be provoked after eating and excess 
alcohol consumption (Feiner et al., 2013; Paz et al., 1996). In the most cases, 
it is a myocardial ischemia associated with microvascular dysfunction, 
increased systolic myocardial stress, and a high gradient in the left ventricular 
outflow tract (Elliott et al., 2014). 
 Syncope is another manifestation of HCM. It is a typical symptom, but 
a possible vasovagal syncope or other mechanism, not associated with the 
disease, should be considered. Typical syncope in HCM patients is associated 
with various mechanisms: hypovolaemia, complete AV block, sinoatrial node 
dysfunction (Barriales-Villa et al., 2010), slow ventricular tachycardia, a sharp 
rise in the left ventricular outflow gradient (McCully et al., 1996), vascular 
dysregulation (Counihan et al., 1991; Prasad et al., 2008), and supraventricular 
arrhythmias with rapid ventricular response (Olivotto et al., 2001). It can be 
expected that in athletes, syncope may be the first and a relatively common 
manifestation of HCM, as they are not related to limiting of a physical 
capacity.  
 The SCD is the most serious manifestation of HCM.  It is mainly due 
to primary ventricular fibrillation, and rarely there are cases of AV block, 
primary asystole and electromechanical dissociation (Nicod et al., 1988; 
Maron et al., 2000). The annual mortality of HCM patients is about 1% - 2% 
(Elliott et al., 2006).  Assessing SCD risk in HCM patients is essential for 
effective clinical behavior and lifestyle recommendations. Risk stratification 
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is based on criteria that are received from anamnesis, physical examination, 
electrocardiography (ECG), Holter ECG, ECG working sample, 
echocardiography (EchoCG). According to AHA's recommendations in 2011, 
the main criteria for risk assessment are: ventricular tachycardia attacks, a 
maximum LV wall thickness over 30 mm, a family history of SCD, 
unexplained syncope, and abnormal response of blood pressure response 
during effort (Gersh et al., 2011). A more recent risk stratification model, 
based on a multicenter retrospective study, was published in 2014 (O’Mahony 
et al., 2014). In addition to the aforementioned criteria (excluding abnormal 
blood pressure reaction), the following were added: left atrium diameter; 
maximal gradient in the LVOT, and age. In this model, the predictive value of 
the SCD for a five-year period has been significantly improved. Based on a 
SCD risk for a five-year period, the patients are divided into three groups – a 
low risk (less than 4% mortality), a moderate risk (4-6% mortality) and a high 
risk (over 6% mortality) (Elliott et al., 2014).  
 The risk of SCD in athletes with HCM is likely to be low in most cases, 
as many of the risk assessment criteria are incompatible with the active 
competitive sports. It should be taken into account that the disease is diagnosed 
earlier in a lot of the athletes (especially in connection with mandatory 
prophylactic examinations) and they are recommended to cease active 
participation in competitive sport. This is confirmed by the data on the low 
general SCD risk in athletes, estimated at around 1 - 3/100000 athletes per 
year (Maron et al., 2009; Van Camp et al., 1995; Corrado et al., 2003; Harmon 
et al., 2011;  Maron et al., 2014).  The results are objective, аlthough most of 
these studies identify the HCM as the most common cause for SCD.  
 
Diagnosis and differential diagnosis of hypertrophic cardiomyopathy 
 It is relatively easy to diagnose HCM, because the basic diagnostic 
criteria is the left ventricular wall hypertrophy, which can be detected by 
different imaging methods; EchoCG, Computed Tomography, and Magnetic 
Resonance Tomography. The hypertrophy may affect one or more segments 
in the absence of causes for a ventricle tension loading (arterial hypertension, 
aortic stenosis, etc.). The phenotypic disease manifestation also includes 
myocardial fibrosis, abnormalities of the mitral valve apparatus, impaired 
coronary microcirculation, and ECG abnormalities (Elliott et al., 2014). The 
diagnosis is certain for adults with a left ventricular wall thickness ≥ 15 mm, 
uncertain at values of 13 - 14 mm, and requires additional criteria such as 
family burden, non-cardiac symptoms, ECG abnormalities, laboratory tests, 
genetic analysis, etc. The main diagnostic criteria in children is the left 
ventricular wall thickness above 2 standard deviations from the mean average.  
 Differential diagnostic problems arise in patients with arterial 
hypertension, valvular diseases, isolated septal hypertrophy in adults, and 
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physiological hypertrophy in athletes. In these cases, a number of additional 
diagnostic criteria are of major importance for the diagnosis. One of the major 
challenges is the differential diagnosis between the LVH in athletes and HCM. 
Incorrect HCM diagnosis or missing this diagnosis in athletes may lead to 
serious health, psychological and socio-economic consequences. The biggest 
differential-diagnosis difficulties occur when the left ventricular wall 
thickness is 13-16 mm, the so-called “gray area”. It is formed for two reasons: 
1. Part of the patients with HCM have a wall thickness of the left ventricle 
below 15 mm (probably 15-20%); 2. Some athletes have a LVH over 12 mm, 
rarely reaching 16 mm. The left-ventricular hypertrophy in athletes always 
should be critically evaluated, taking into account a sports discipline, sports 
qualification, stage of preparation, age, gender, race, and other factors. The 
significance of these factors is mentioned in a number of studies that have 
detected a left-ventricular hypertrophy over 12 mm in a small part of the 
athletes (about 2% of the white race and about 15% of the black race) 
(Pelliccia et al., 1991; Basavarajaiah et al., 2008). Most often, hypertrophy 
occurs in cyclists, rowers, and ski runners.  
 The differential diagnosis for athletes who fall in the “gray area’’ is 
based on data from a number of studies - current complaints, family history, 
ECG, EchoCG, ECG stress tests (including gas analysis), magnetic resonance 
tomography, and genetic tests. All of these methods can help to diagnose, but 
some of the parameters obtained may have greater differential-diagnosis 
value. Several studies have been conducted in this direction. Some of them 
compared the results of studies in athletes with a LVH to the HCM patients 
(Sharma et al., 2002; Vinereanu et al., 2001; Caselli et al., 2014; Grazioli et 
al., 2016). Other studies compare athletes with a LVH to sport active people 
with HCM, which is likely to lead to more correct conclusions (Sheikh et al., 
2013; Malhotra et al., 2014). According to these studies, the most important 
differential-diagnosis criteria are the following: a relative septum thickness 
versus a left ventricular cavity diameter, inversion of the T-wave, spatial QRS-
T angle over 45 degrees, left ventricular cavity diameter, left atrium diameter, 
ratio of E-wave to A-wave of the mitral diastolic blood flow, and family 
burden. In the various studies, the severity of these parameters is assessed 
differently. The relative septum thickness and the left ventricular cavity 
diameter most likely have the greatest differential-diagnostic value. 
 
Conclusion 
 One of the most significant issues concerns behaviors in athletes 
diagnosed with HCM. The correct decision relates to the following findings 
from studies that have already been completed: 1. HCM is the most common 
or one of the most common causes of SCD in athletes; 2. It is likely that the 
incidence of SCD in athletes with HCM is lower than in individuals with this 
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disease who do not exercise; 3. There is no reliable evidence that the SCD in 
athletes occurs more often during physical activity; 4. The risk stratification 
from a SCD shows that it is different for the individual HCM patients; 5. It is 
likely that physical exertions, on one hand, may increase the risk of the SCD, 
but on the other hand, they bring certain benefits in terms of the quality of life, 
and perhaps in terms of prognosis (Klempfner et al.,  2015); 6. In genotype-
positive persons, without phenotypic expression, the risk of SCD is very low; 
7. Implantable cardioverter defibrillator is effective in prevention the SCD 
(Lampert et al., 2013). Taking into account all this information, it seems that 
the most appropriate behavior is the individual approach to every athlete. 
However, according to the recommendations of the European Cardiology 
Society, all athletes with HCM diagnosis, including phenotype-negative, 
should cease participating in active competitive sports (Elliott et al., 2014). 
The recommendations of the American Cardiology Association are more 
liberal (Maron et al., 2015): 1. Participation in competitive sports of HCM 
genotype-positive individuals without phenotypic expression is acceptable; 2. 
Individuals with clinically proven HCM should not participate in competitive 
sports, except in those with low intensity. Perhaps in the future, on the basis 
of more precise risk stratification, an individual approach will be adopted for 
the HCM patients in terms of the sports activity. 
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